Pharmacogenetics in Primary Care Psychotropics

Phase 3

• Conditions: Obsessive-Compulsive Disorder; Generalized Anxiety Disorder; Depression
• Interventions: Diagnostic Test: Pharmacogenetic testing

• Registration Number: NCT03232502
• Lead Sponsor: University of Arizona

Brief Summary

Pragmatic trial of pharmacogenetic testing at the time of prescription for a selective serotonin reuptake inhibitor, tricyclic antidepressant or atypical antipsychotic. Does real time intervention improve patient outcomes?

Detailed Description

Not available

Study Timeline

• Status Verified: 2017-07
• Study First Submitted: 2017-07-24
• Study First Submitted QC: 2017-07-26
• Last Update Submitted: 2017-07-26
• Study First Posted: 2017-07-28
• Last Update Posted: 2017-07-28
• Study Start: 2017-08-15
• Primary Completion: 2018-01-15
• Study Completion: 2018-12-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 130

Inclusion Criteria

• Over 18
• Prescribed a drug of interest for the first time

Exclusion Criteria

• Previous pharmacogenetic testing available

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Intervention	Pharmacogenetic testing	-

Primary Outcome Measures

Name	Time	Method
Patient oriented outcome1- Clinical Improvement	6 months	Clinically significant improvement as noted by physician (Subjective and PHQ-9)
Patient oriented outcome2- Adverse effects	6 months	Number of patients with specific, common side effects (from medical chart)
Patient oriented outcome3- Time to Improvement	Up to 6 months	Days to clinical improvement (from medical chart)
Patient oriented outcome5- Visits	6 months	Total number of visits to clinic with medication titration required (from medical chart)